(Q34418911)

2 August 2017

title

Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies (English)

1 reference

2 August 2017

0 references

4

Robert E W Hancock

1 reference

2 August 2017

3

John H Boyd

1 reference

2 August 2017

Ngan H Lyle

1

1 reference

2 August 2017

Olga M Pena

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

2 May 2014

1 reference

Annals of the New York Academy of Sciences

2 August 2017

published in

1 reference

2 August 2017

volume

1323

1 reference

2 August 2017

page(s)

101-114

1 reference

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

The Surviving Sepsis Campaign: raising awareness to reduce mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Global trends in emerging infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

2012 and beyond: potential for the start of a second pre-antibiotic era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

CTX-M: changing the face of ESBLs in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Fourteen years in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Excess deaths associated with tigecycline after approval based on noninferiority trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Conventional and molecular techniques for the early diagnosis of bacteraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

The potential for PCR based testing to improve diagnosis and treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Cytokines and signaling molecules predict clinical outcomes in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Sepsis: a new hypothesis for pathogenesis of the disease process

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

A genomic storm in critically injured humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Immunosuppression in patients who die of sepsis and multiple organ failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Vasopressin versus norepinephrine infusion in patients with septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Human recombinant lactoferrin for sepsis: too good to be true?.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Issues in the adjunct therapy of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Novel strategies for the treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Broken barriers: a new take on sepsis pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

THE ROLE OF MICROBIC VIRULENCE, DOSAGE, AND HOST RESISTANCE IN DETERMINING THE SPREAD OF BACTERIAL INFECTIONS AMONG MICE : I. PASTEURELLA LEPISEPTICA AND PASTEURELLA AVISEPTICA INFECTIONS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Comparison of two fluid-management strategies in acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Sepsis and septic shock: a history

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Historical perspective of the word "sepsis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Sepsis definitions: time for change

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Classification of sepsis, severe sepsis and septic shock: the impact of minor variations in data capture and definition of SIRS criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Invasive methicillin-resistant Staphylococcus aureus infections among patients on chronic dialysis in the United States, 2005-2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

21 January 2018

Severe peripartum sepsis

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Bench-to-bedside review: Association of genetic variation with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Drotrecogin alfa (activated) in adults with septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Recombinant Human Activated Protein C for Adults with Septic Shock. A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Sepsis mortality prediction based on predisposition, infection and response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Predisposition, insult/infection, response, and organ dysfunction: A new model for staging severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Comparison of Predisposition, Insult/Infection, Response, and Organ dysfunction, Acute Physiology And Chronic Health Evaluation II, and Mortality in Emergency Department Sepsis in patients meeting criteria for early goal-directed therapy and the sev

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

The predisposition, infection, response and organ failure (Piro) sepsis classification system: results of hospital mortality using a novel concept and methodological approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Evaluation of community-acquired sepsis by PIRO system in the emergency department.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Tracking the microbes in sepsis: advancements in treatment bring challenges for microbial epidemiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

The response of the host microcirculation to bacterial sepsis: does the pathogen matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Enabling a systems biology approach to immunology: focus on innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

The effect of age on the development and outcome of adult sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

The immunopathogenesis of sepsis in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

The epidemiology of sepsis in patients with malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Diabetes and sepsis: preclinical findings and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

The impact of diabetes on the pathogenesis of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12444

21 January 2018

Identifiers

DOI

10.1111/NYAS.12444

1 reference

2 August 2017

1 reference